Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Equivalence Study of MYL-1401A vs Humira in Moderate-to-Severe Chronic Plaque Psoriasis
2014-003420-46Phase 3Completed
- Sponsor
- Mylan
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriasis comparing MYL-1401A with Humira (2 arms). Primary endpoint: Percent improvement in PASI from baseline to Week 12. Started Apr 2015; status: completed.
02
Drugs
MYL-1401Aadalimumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2014-003420-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003420-46.